Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA ; volume:24 ; number:1 ; day:16 ; month:8 ; year:2024 ; pages:1-11 ; date:12.2024
BMC cancer ; 24, Heft 1 (16.8.2024), 1-11, 12.2024
- Creator
-
Chen, Jennifer H.
Addanki, Sridevi
Roy, Dhruvajyoti
Bassett, Roland
Kalashnikova, Ekaterina
Spickard, Erik
Kuerer, Henry M.
Meas, Salyna
Sarli, Vanessa N.
Korkut, Anil
White, Jason B.
Rauch, Gaiane M.
Tripathy, Debu
Arun, Banu K.
Barcenas, Carlos H.
Yam, Clinton
Sethi, Himanshu
Rodriguez, Angel A.
Liu, Minetta C.
Moulder, Stacy L.
Lucci, Anthony
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-024-12689-6
- URN
-
urn:nbn:de:101:1-2411032100236.358880767711
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chen, Jennifer H.
- Addanki, Sridevi
- Roy, Dhruvajyoti
- Bassett, Roland
- Kalashnikova, Ekaterina
- Spickard, Erik
- Kuerer, Henry M.
- Meas, Salyna
- Sarli, Vanessa N.
- Korkut, Anil
- White, Jason B.
- Rauch, Gaiane M.
- Tripathy, Debu
- Arun, Banu K.
- Barcenas, Carlos H.
- Yam, Clinton
- Sethi, Himanshu
- Rodriguez, Angel A.
- Liu, Minetta C.
- Moulder, Stacy L.
- Lucci, Anthony
- SpringerLink (Online service)
Other Objects (12)
Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Microwave imaging for neoadjuvant chemotherapy monitoring: initial clinical experience
Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer
Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
Does T1c–2N0–1M0 triple negative breast cancer derive a benefit from neoadjuvant chemotherapy?
Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Microwave imaging for neoadjuvant chemotherapy monitoring: initial clinical experience
Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer
Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
Does T1c–2N0–1M0 triple negative breast cancer derive a benefit from neoadjuvant chemotherapy?
Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Microwave imaging for neoadjuvant chemotherapy monitoring: initial clinical experience
Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer
Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience